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Background and Purpose  Responses to repetitive nerve stimulation (RNS) in patients 
with muscle-specific tyrosine kinase (MuSK) antibody (Ab)-positive myasthenia gravis (MG) 
vary depending on the muscles tested. We analyzed the RNS responses of limb and facial 
muscles in MuSK-Ab-positive and acetylcholine receptor (AChR)-Ab-negative MG (MuSK 
MG) and MuSK-Ab-negative and AChR-Ab-negative [double-seronegative (DSN)] MG pa-
tients.
Methods  We retrospectively compared RNS responses between 45 MuSK MG and 29 DSN 
MG. RNS was applied to the abductor digiti minimi, flexor carpi ulnaris, trapezius, orbicu-
laris oculi, and nasalis muscles.
Results  Abnormal RNS responses in limb muscles were observed in 22.2 and 58.6% of 
MuSK MG and DSN MG patients, respectively, with abnormal facial responses observed in 
77.8 and 65.5%, and abnormal responses observed in any of the five muscles in 86.7 and 
72.4%. Abnormal RNS responses in the abductor digiti minimi or flexor carpi ulnaris were 
less frequent in MuSK MG (8.9 and 15.6%, respectively) than in DSN MG (37.9 and 55.2%), 
whereas the findings for other muscles were not significantly different between the groups. 
Abnormal facial responses but normal limb responses were independently associated with 
MuSK MG (odds ratio=5.224, 95% confidence interval=1.300–20.990).
Conclusions  Abnormal RNS responses primarily in facial muscles without involvement of 
limb muscles were more pronounced in MuSK MG than in DSN MG. RNS of both facial and 
limb muscles in AChR-Ab-negative MG can increase the test sensitivity and aid in early suspi-
cion of MuSK MG.
Key Words   MuSK, muscle-specific tyrosine kinase, myasthenia gravis, repetitive nerve 
stimulation, acetylcholine receptor.
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INTRODUCTION
Myasthenia gravis (MG) is a relatively rare autoimmune disorder characterized by fatiga-
ble weakness of voluntary muscles.1,2 Since impaired neuromuscular transmission is the 
main pathomechanism of MG, identifying this is essential in an MG diagnosis. Therefore, 
electrodiagnostic studies including repetitive nerve stimulation (RNS) testing are impor-
tant diagnostic tools, especially in patients without antibodies (Abs) to the acetylcholine 
receptor (AChR).
Typically 40–70% of generalized MG patients without AChR Abs have Abs to muscle-
specific tyrosine kinase (MuSK).3-6 The few studies in which RNS was performed in patients 
with MuSK-Ab-positive MG produced wide ranges for the proportion of patients with ab-
normal responses (12% to 86%).7-10 These previous studies were heterogeneous with respect 
to the nerve–muscle sets studied in the RNS: whereas some studies performed RNS only in 
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limb muscles,3,7 others performed RNS in both limb and fa-
cial muscles.5,10-12 Also, most previous studies had small pop-
ulations.5,6,9 
The aim of the present study was to determine the differ-
ence in sensitivity of RNS according to the tested muscles 
and reveal any distinctive RNS features of MuSK-Ab-posi-
tive MG patients among AChR-Ab-negative MG patients. 
We analyzed the RNS responses of limb and facial muscles 
in MuSK-Ab-positive and AChR-Ab-negative MG (MuSK 
MG) patients and compared the results with those of MuSK-
Ab-negative and AChR-Ab-negative [double-seronegative 
(DSN)] MG patients. 
METHODS
Subjects
We retrospectively reviewed medical records of MG patients 
between January 1992 and December 2015 in Severance 
Hospital. The diagnosis of MG was based on clinical symp-
toms and signs of muscle fatigue, decremental responses to 
low-frequency RNS, serum levels of AChR and MuSK Abs, 
and improvement of muscle fatigue after the intramuscular 
injection of neostigmine. The following inclusion criteria were 
used: 1) completed AChR Ab and MuSK Ab assay, 2) negative 
AChR Ab results, and 3) RNS performed in all of five muscles 
(abductor digiti minimi, flexor carpi ulnaris, nasalis, orbi-
cularis oculi, and trapezius). In total, 81 AChR-Ab-negative 
MG patients met the inclusion criteria, of which 8 with pure 
ocular MG at the time of RNS and 1 with concomitant diag-
nosis of amyotrophic lateral sclerosis were excluded. All of 
the pure ocular cases were DSN MG patients. Finally, data 
from 45 MuSK MG patients (i.e., negative for AChR Ab and 
positive for MuSK Ab) and 29 DSN MG patients (i.e., nega-
tive for both AChR and MuSK Abs) were analyzed. The Uni-
versity of Yonsei Institutional Review Board approved this 
research (Approval No. 4-2016-0775). 
Diagnostic testing 
RNS was performed using the method of Oh et al.13 in five 
muscles: the abductor digiti minimi and flexor carpi ulnaris 
after ulnar nerve stimulation, the orbicular oculi and nasa-
lis after facial nerve stimulation, and the trapezius after spi-
nal accessory nerve stimulation. Nerve stimulation was per-
formed by delivering supramaximal stimulation for 0.2 ms. 
The compound muscle action potential (CMAP) was record-
ed in each tested muscle at baseline and immediately after 
30 seconds of muscle exercise. Low-frequency RNS was per-
formed at 1, 3, and 5 minutes after exercise, with five 3-Hz stim-
ulations delivered at 3 minutes after exercise. The responses to 
RNS at 3 minutes after exercise were analyzed in this study. 
The ratio between the first CMAP and the lowest CMAP among 
the first five waveforms was calculated. A decrement in CMAP 
of ≥10% was considered abnormal. In those patients taking 
anticholinesterase agents, RNS was conducted at least 12 
hours after the last dose. RNS was conducted using the Neu-
roscreen System (Toennies, Bavaria, Germany) or the Schwar-
zer topas EMG system (Natus, Bavaria, Germany). The AChR 
Ab was analyzed using a commercially available assay (anti-
AChR-binding Ab, Seoul Clinical Laboratories, Seoul, Korea), 
with the result considered negative when the Ab level was 
≤0.2 nmol/L. An anti-MuSK Ab assay was also conducted us-
ing a commercially available assay (anti-MuSK Ab, Athena Di-
agnostics, Worcester, MA, USA), with the results categorized 
into negative (<10 titer units), borderline (≥10 titer units and 
<20 titer units), or positive (≥20 titer units); those patients cat-
egorized as positive were included in the MuSK MG group.
Data collection
Clinical features including age, sex, age at symptom onset, 
age at initial RNS, symptoms at disease onset, Myasthenia 
Gravis Foundation of America (MGFA) clinical classifica-
tion, quantitative myasthenia gravis (QMG) score, state of 
immunosuppressive treatment, and presence of MG crisis 
were collected by reviewing medical records. RNS results at 
the time of initial visit to our clinic were also recorded based 
on electrodiagnostic reports. 
Statistical analysis
Fisher’s exact test or the chi-square test was used to compare 
categorical variables, and the t-test or Mann-Whitney test 
was used to compare continuous variables. The associations 
between clinical and electrodiagnostic variables and MuSK 
MG were evaluated using multiple logistic regression analy-
ses. Covariates with p value <0.1 in the univariate analyses 
were included in multivariate analyses. Because of the rela-
tively small sample, the MGFA classification was included as 
a representative of clinical features in the multivariate analy-
sis. Patients who were assigned a MGFA classification of “b” 
were regarded as those with bulbar predominance. All statis-
tical analyses were two-tailed, and a p value <0.05 was consid-
ered to be statistically significant. Statistical analyses were 
performed using R software (version 3.2.2, R Foundation, 
Vienna, Austria).
RESULTS
Clinical characteristics
The clinical features in the MuSK MG and DSN MG groups 
are listed in Table 1. The proportion of females was greater 
in the MuSK MG group (91.1%) than in the DSN MG group 
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(65.5%, p=0.006). Bulbar and respiratory symptoms were 
more frequent in the MuSK MG group (91.1 and 31.1%) 
than in the DSN MG group (65.5 and 6.9%, p=0.006 and 
0.014, respectively). A MGFA classification of IV or V was 
more frequent in the MuSK MG group (33.3%) than in the 
DSN MG group (6.9%, p=0.008). Among the subgroup of 
patients whose QMG scores were recorded, the total QMG 
score did not differ between the two groups. However, the 
QMG score for bulbar and facial weakness was higher in 
MuSK MG (3.6±1.9, mean±standard deviation) than in DSN 
MG (1.3±2.1, p=0.001). The state of immunosuppressive 
treatment or the presence of an MG crisis before the initial 
RNS did not differ between the two groups.
Comparison of repetitive nerve stimulation
between groups
The RNS results for the MuSK MG and DSN MG groups are 
presented in Table 2. Abnormal RNS responses in the ab-
ductor digiti minimi or flexor carpi ulnaris occurred less fre-
quently in the MuSK MG group (8.9 and 15.6%) than in 
the DSN MG group (37.9 and 55.2%, p=0.002 and p<0.001, 
respectively). By contrast, the proportions of abnormal RNS 
responses in the trapezius, orbicularis oculi, and nasalis mus-
cles were not significantly different across the groups. The 
magnitude of the CMAP decrement showed similar patterns. 
The CMAP decrement in the abductor digiti minimi or flex-
or carpi ulnaris muscles was significantly greater in the DSN 
MG group (-15.03 and -24.35%, respectively) than in the 
MuSK MG group (-2.35 and -3.67%, p=0.002 and 0.001, re-
spectively). In contrast, the CMAP decrement in the orbicu-
Table 1. Clinical features of MuSK-Ab-positive and AChR-Ab-negative MG (MuSK MG) patients and MuSK-Ab-negative and AChR-Ab-negative 
(DSN) MG patients at the time of an initial RNS test
MuSK MG (n=45) DSN MG (n=29) p
Sex, female 41 (91.1) 19 (65.5) 0.006
Age at onset, years 37.0 (27.0–44.0) 35.0 (26.0–46.5) 0.982
Age at time of RNS, years 40.0 (29.5–46.0) 37.0 (28.5–47.0) 0.820
Symptoms at time of RNS
Ocular 34 (75.6) 22 (75.9) 0.976
Bulbar 41 (91.1) 19 (65.5) 0.006
Limb 23 (51.1) 17 (58.6) 0.527
Neck 22 (48.9) 16 (55.2) 0.598
Respiratory 14 (31.1) 2 (6.9) 0.014
MGFA classification at time of RNS 0.049
Class II 16 (35.6) 17 (58.6)
Class III 14 (31.1) 10 (34.5)
Class IV 5 (11.1) 0 (0)
Class V 10 (22.2) 2 (6.9)
Severity (MGFA II+III:IV+V) 30:15 27:2 0.008
MGFA “b” classification at time of RNS 36 (80.0) 9 (31.0) <0.001 
QMG score at the time of RNS*
Total  11.8±4.9 9.7±6.8 0.263
Ocular 2.9±2.1 3.1±2.5 0.844
Bulbar and facial 3.6±1.9 1.3±2.1 0.001
Limb 3.4±2.8 4.2±3.1 0.361
Respiratory 0.8±1.1 0.4±0.7 0.119
Neck 1.1±1.2 0.8±1.0 0.376
Immunosuppressive treatment at time of RNS 0.333
RNS before treatment 26 (57.8) 20 (69.0)
RNS during treatment 19 (42.2) 9 (31.0)
Crisis before RNS 10 (22.2) 2 (6.9)  0.110
Data are n (%), mean±standard deviation, or median (interquartile range) values.
*QMG scores at the time of initial RNS were recorded in 22 MuSK MG and 19 DSN MG patients.
Ab: antibody, AChR: acetylcholine-receptor, DSN: double-seronegative, MG: myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America, 
MuSK: muscle-specific tyrosine kinase, QMG: quantitative myasthenia gravis, RNS: repetitive nerve stimulation. 
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laris oculi, nasalis, and trapezius muscles did not differ be-
tween the two groups. 
The anatomical distribution of abnormal RNS responses 
differed between MuSK MG and DSN MG. An RNS pattern 
that was abnormal in facial muscles (abnormal in either the 
orbicularis oculi or nasalis) and normal in limb muscles 
(normal in both the abductor digiti minimi and flexor carpi 
ulnaris) occurred significantly more frequently in the MuSK 
MG group (60%) than in the DSN MG group (13.8%, p<0.001). 
A pattern that was abnormal in both facial and limb muscles 
was more frequent in DSN MG (51.7%) than in MuSK MG 
(17.8%, p=0.002).
Multivariate analysis
Multiple logistic regression analysis was performed to assess 
clinical and electrodiagnostic factors associated with MuSK 
MG. In univariate analysis, female sex, bulbar MGFA classi-
fication, severity of disease, and RNS patterns that were ab-
normal in the face but normal in limbs were related to MuSK 
MG. In multivariate analysis, bulbar MGFA classification [odds 
Table 2. Initial RNS results for MuSK MG and DSN MG patients
MuSK MG (n=45) DSN MG (n=29) p
Abnormal responses 
ADM 4 (8.9) 11 (37.9) 0.002
FCU 7 (15.6) 16 (55.2) <0.001
TR 17 (37.8) 14 (48.3) 0.372
OO 27 (60.0) 16 (55.2) 0.681
NA 29 (64.4) 17 (58.6) 0.614
Any muscle 39 (86.7) 21 (72.4) 0.126
Limb (FCU or ADM) 10 (22.2) 17 (58.6) 0.001
Face (NA or OO) 35 (77.8) 19 (65.5) 0.246
Pattern of abnormal RNS responses
Abnormal in both limbs and face 8 (17.8) 15 (51.7) 0.002
Abnormal only in face 27 (60.0) 4 (13.8) <0.001
Abnormal only in limbs 2 (4.4) 2 (6.9) 0.642
Normal in both limbs and face 8 (17.8) 8 (27.6) 0.317
CMAP decrement (%)
ADM -2.35±6.44 -15.03±19.36 0.002
FCU -3.67±8.54 -24.35±30.74 0.001
TR -11.53±14.56 -15.49±17.15 0.289
OO -16.74±16.51 -19.82±25.97 0.531
NA -16.37±12.96 -23.46±23.78 0.149
Data are n (%) or mean±standard deviation values.
ADM: abductor digiti minimi, CMAP: compound muscle action potential, DSN: double-seronegative, FCU: flexor carpi ulnaris, MG: myasthenia gravis, 
MuSK: muscle-specific tyrosine kinase, NA: nasalis, OO: orbicularis oculi, RNS: repetitive nerve stimulation, TR: trapezius.
Table 3. Results of univariate and multivariate analyses evaluating the clinical and electrodiagnostic factors associated with MuSK MG compared 
to DSN MG
Variable
Univariate logistic regression Multivariate logistic regression
OR 95% CI p OR 95% CI p
Age at onset 0.995 0.954–1.037 0.801
Sex, female 5.359 1.499–19.418 0.010 1.655 0.350–7.826 1.655
MGFA “b” at time of RNS 8.889 3.038–26.006 <0.001 6.410 1.892–21.718 0.003
Disease severity at time of RNS
MGFA II+III Reference Reference
MGFA IV+V 6.750 1.412–32.262 0.017 3.466 0.575–20.897 0.175
Abnormal RNS response in the face and 
  normal RNS response in limbs
9.375 2.789–31.512 <0.001 5.224 1.300–20.990 0.020
Immunosuppressive treatment before RNS 1.624 0.607–4.346 0.334
CI: confidence interval, DSN: double-seronegative, MG: myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America, MuSK: muscle-specific 
tyrosine kinase, OR: odds ratio, RNS: repetitive nerve stimulation.
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ratio (OR)=6.410, 95% confidence interval (CI)=1.892–21.718] 
and RNS patterns that were abnormal in the face but normal 
in limbs (OR=5.224, 95% CI=1.300–20.990) were found to 
be independently associated with MuSK MG (Table 3).
Change in sensitivity of repetitive nerve stimulation
Overall, abnormal responses in any of the five muscles were 
observed in 86.7% of MuSK MG patients and 72.4% of DSN 
MG patients (Fig. 1). Abnormal responses in limb muscles 
were observed in 22.2% of MuSK MG patients and 58.6% 
of DSN MG patients. When the trapezius muscle was addi-
tionally evaluated, the proportion of abnormal responses 
increased to 48.9% in the MuSK MG group, whereas the sen-
sitivity did not change in the DSN MG group. When con-
sidering both the limb and facial muscles, the proportion of 
patients with abnormal RNS responses increased to 82.2% in 
the MuSK MG group and 72.4% in the DSN MG group.
DISCUSSION
Abnormal RNS responses of limb muscles occurred less 
frequently in MuSK MG patients than in DSN MG patients. 
A pattern of abnormal facial muscle responses but normal 
limb muscle responses was more frequent in MuSK MG 
patients than in DSN MG patients. Whereas the proportion 
of MuSK MG patients with abnormal responses was 22.2% 
when considering only limb muscles, this increased to 82.2% 
when the orbicularis oculi and nasalis muscles were also 
evaluated. By contrast, the additional evaluation of facial 
muscles in DSN MG patients increased the sensitivity by 
only 13.8%. These findings suggest that abnormal RNS re-
sponses primarily in facial muscles without involvement of 
distal limb muscles are more pronounced in MuSK MG than 
in DSN MG, and that performing RNS in both the face and 
limbs can increase the test sensitivity.
Our findings are consistent with those of previous stud-
ies. Some of the previous studies found a low sensitivity of 
RNS in MuSK-Ab-positive MG patients, but they only per-
formed RNS in hand or shoulder muscles and not in facial 
muscles.6,7 Consistent with this, we found abnormal RNS 
responses in limb muscles in only 22.2% of MuSK MG pa-
tients. Other studies that performed RNS in both limb and 
facial muscles found abnormal responses to be more com-
mon in facial muscles (75–80%) than in limb muscles (25–
36%).8,11,14 In the present study, the sensitivities of RNS in 
the facial and limb muscles were 77.8 and 22.2%, respective-
ly. In addition, the RNS responses tended to be abnormal 
only in the face, and rarely in both the face and limbs, which 
is consistent with a previous study suggesting focal muscle 
involvement in MuSK-Ab-positive MG.10 
The proportion of abnormal RNS responses in the pres-
ent DSN MG patients is also consistent with previous stud-
ies. Abnormal RNS responses were reportedly observed in 
30–74% of subjects in facial muscles and in 36–78% of sub-
jects in limb muscles.3,9,11,12 Similarly, in the present study, 
the RNS responses of facial and limb muscles were abnor-
mal in 65.5 and 58.6% of DSN MG patients, respectively.
The strengths of the present study include its relatively 
large population and the similarity of the methods used to 
perform RNS across patients. By contrast, previous studies 
have included relatively small populations or recruited pa-
tients from different institutions, and did not perform RNS 
in the same muscles.8,9,14 Also, in the present study we were 
able to calculate the sensitivity of RNS in each tested mus-
cle and demonstrate how the sensitivity changed as the num-
ber of muscles tested increased. This revealed that addition-
ally evaluating the orbicularis oculi and nasalis muscles 
increased the overall sensitivity in MuSK MG by 60%. 
Early suspicion of MuSK-Ab-positive MG is important 
since this condition is often associated with rapid disease pro-
gression, frequent respiratory crisis, poor response to cholin-
esterase inhibitor, and early requirement of immunosuppres-
sive treatment.15,16 Because bulbar and facial muscle weakness 
is prominent in MuSK-Ab-positive MG, this condition can 
Fig. 1. Abnormal rate of repetitive nerve stimulation responses depending on the site of examination in (A) muscle-specific tyrosine kinase-anti-
body-positive myasthenia gravis group and (B) double-seronegative myasthenia gravis group. NA: nasalis, OO: orbicularis oculi, TR: trapezius.
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be suspected based on clinical characteristics. However, a 
differential diagnosis is difficult based solely on clinical data. 
In the present study, abnormal RNS responses primarily in 
facial muscles were shown to be independently associated 
with MuSK MG after adjusting for sex, disease severity, and 
clinical presentation. RNS is usually performed when MG 
is initially suspected, with the results being immediately avail-
able to physicians after the test. Thus, identification of the typi-
cal RNS pattern of MuSK MG can contribute to early diag-
noses. 
In conclusion, conducting RNS in multiple muscles in-
cluding those of the face and limbs in AChR-Ab-negative MG 
patients increases the diagnostic sensitivity and may be help-
ful in differentiating MuSK MG from DSN MG. 
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